zum Directory-modus


Interferone für topische Anwendungen in der Virus-Therapie

Interferone wurden unter anderem im Hinblick auf topische Anwendungen untersucht - also eine Anwendung in geringer Dosierung in Form von Nasensprays, Gelen oder Cremes. IFN-α und -β können in Form eines Nasensprays zwar die Vermehrung von Schnupfenviren (Rhinoviren, Coronaviren) teilweise verhindern, aber sobald sich eine Infektion erst einmal im Körper etabliert hat, sind Interferone mehr oder weniger wirkungslos. Vermutlich beruht der positive Effekt der Interferone hier eher auf einer generellen Stimulation des Immunsystems.

Die topische Anwendung von IFN-α und -β als Hautcreme bei Infekten mit dem Herpes-zoster-Virus oder bei Genitalwarzen durch Papilloma-Viren (Condyloma acuminatum) zeigte ebenfalls nur eine begrenzte Wirksamkeit. Die Wirkung war etwas größer, wenn Interferone intramuskulär gespritzt oder intravenös verabreicht wurden, aber nicht so groß, als dass Interferone zur Therapie der Wahl bei diesen Erkrankungen geeignet wären.


Gao, L.; Yu, S.; Chen, Q.; Duan, Z.; Zhou, Y.; Mao, C.; Yu, D.; Zhu, W.; Nie, J.; Hou, Y. (2010): A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits.. In: Vaccine. 28 , 4445-51
Titel des Artikels
A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits.
The military population has a high disease burden of acute viral respiratory infections in China. To assess the efficacy and safety of a low-dose recombinant human interferon alpha-2b (rIFNalpha-2b) nasal spray in preventing acute viral respiratory infections in military population, we performed this randomized controlled trial. The results showed that application of the rIFNalpha-2b nasal spray had the benefits in prevention of infections caused by influenza A virus, influenza B virus parainfluenza viruses 1-3 and adenovirus species B. However, no benefit was seen in preventing respiratory syncytial virus. No severe adverse events were reported. Therefore, the rIFNalpha-2b nasal spray was effective and well tolerated for preventing common viral respiratory infections in the military recruits.
Himmler, A.; Buck, W. H. (2010 ): Warts (genital). In: Clin. Evid. (Online). 7 , 1602
Titel des Artikels
Warts (genital)
External genital warts (EGWs) are sexually transmitted benign epidermal growths caused by the human papillomavirus (HPV), on the anogenital areas of both females and males. About 50% to 60% of sexually active women aged 18 to 49 years have been exposed to HPV infection, but only 10% to 15% will have genital warts. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for external genital warts? What are the effects of interventions to prevent transmission of external genital warts? We searched: Medline, Embase, The Cochrane Library, and other important databases up to December 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 55 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: bi- and trichloroacetic acid; condoms; cryotherapy; electrosurgery; imiquimod; intralesional, topical, or systemic interferons; laser surgery; podophyllin; podophyllotoxin; surgical excision; and vaccines.
Seite 17 von 20